Tags

Type your tag names separated by a space and hit enter

COVID-19 in teriflunomide-treated patients with multiple sclerosis.
J Neurol. 2020 Jun 03 [Online ahead of print]JN

Abstract

The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

Authors+Show Affiliations

Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.Department of Neurology, University of Massachusetts, Worcester, MA, USA.Department of Neurology, Maine Medical Center, Portland, ME, USA.Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.Department of Neurology, Concord Hospital, Concord, NH, USA.Department of Neurology, University of Massachusetts, Worcester, MA, USA.Department of Neurology, Maine Medical Center, Portland, ME, USA.Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, Milan, Italy.Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA. rbakshi@post.harvard.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32494856

Citation

Maghzi, Amir Hadi, et al. "COVID-19 in Teriflunomide-treated Patients With Multiple Sclerosis." Journal of Neurology, 2020.
Maghzi AH, Houtchens MK, Preziosa P, et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020.
Maghzi, A. H., Houtchens, M. K., Preziosa, P., Ionete, C., Beretich, B. D., Stankiewicz, J. M., Tauhid, S., Cabot, A., Berriosmorales, I., Schwartz, T. H. W., Sloane, J. A., Freedman, M. S., Filippi, M., Weiner, H. L., & Bakshi, R. (2020). COVID-19 in teriflunomide-treated patients with multiple sclerosis. Journal of Neurology. https://doi.org/10.1007/s00415-020-09944-8
Maghzi AH, et al. COVID-19 in Teriflunomide-treated Patients With Multiple Sclerosis. J Neurol. 2020 Jun 3; PubMed PMID: 32494856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 in teriflunomide-treated patients with multiple sclerosis. AU - Maghzi,Amir Hadi, AU - Houtchens,Maria K, AU - Preziosa,Paolo, AU - Ionete,Carolina, AU - Beretich,Biljana D, AU - Stankiewicz,James M, AU - Tauhid,Shahamat, AU - Cabot,Ann, AU - Berriosmorales,Idanis, AU - Schwartz,Tamara H W, AU - Sloane,Jacob A, AU - Freedman,Mark S, AU - Filippi,Massimo, AU - Weiner,Howard L, AU - Bakshi,Rohit, Y1 - 2020/06/03/ PY - 2020/05/01/received PY - 2020/05/20/accepted PY - 2020/05/18/revised PY - 2020/6/5/entrez PY - 2020/6/5/pubmed PY - 2020/6/5/medline KW - Antiviral KW - COVID-19 KW - Coronavirus KW - Multiple sclerosis KW - Teriflunomide JF - Journal of neurology JO - J. Neurol. N2 - The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic. SN - 1432-1459 UR - https://www.unboundmedicine.com/medline/citation/32494856/COVID-19_in_teriflunomide-treated_patients_with_multiple_sclerosis L2 - https://dx.doi.org/10.1007/s00415-020-09944-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.